BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
Raunak ShresthaNoushin NabaviYen-Yi LinFan MoShawn AndersonStanislav VolikHans H AdomatDong LinHui XueXin DongRobert ShukinRobert H BellBrian McConeghyAnne HaegertSonal BrahmbhattEstelle LiHtoo Zarni OoAntonio Hurtado-CollLadan FazliJoshua ZhouYarrow McConnellAndrea McCartAndrew LowyGregg B MorinTianhui ChenMads DaugaardS Cenk SahinalpFaraz HachStephane Le BihanMartin E GleaveYuzhuo WangAndrew ChurgColin C CollinsPublished in: Genome medicine (2019)
Our findings reveal BAP1 to be a potential, easily trackable prognostic and predictive biomarker for PeM immunotherapy that refines PeM disease classification. BAP1 stratification may improve drug response rates in ongoing phases I and II clinical trials exploring the use of immune checkpoint blockade therapies in PeM in which BAP1 status is not considered. This integrated molecular characterization provides a comprehensive foundation for improved management of a subset of PeM patients.